NRX Pharmaceuticals (NRXP) Restructuring Costs (2023 - 2026)

NRX Pharmaceuticals (NRXP) has 4 years of Restructuring Costs data on file, last reported at -$6000.0 in Q1 2026.

• On a quarterly basis, Restructuring Costs fell 106.0% year-over-year to -$6000.0 in Q1 2026; TTM through Mar 2026 was -$70000.0, a 93.65% increase from a year earlier, with the FY2025 full-year figure at $36000.0, up 103.0% from the prior year.
• Restructuring Costs for Q1 2026 stood at -$6000.0, down from $30000.0 in the prior quarter.
• Over the last five years, Restructuring Costs for NRXP reached as high as $250000.0 in Q2 2023 and fell as low as -$1.2 million in Q4 2024.
• Historically, Restructuring Costs has averaged -$117428.6 across 4 years, with a median of $30000.0 in 2025.
• Across the five-year window, Restructuring Costs jumped 102.5% in 2025 and slumped 106.0% in 2026, its largest moves.
• Year by year, Restructuring Costs stood at $250000.0 in 2023, then slumped by 580.8% to -$1.2 million in 2024, then soared by 102.5% to $30000.0 in 2025, then slumped by 120.0% to -$6000.0 in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were -$6000.0 in Q1 2026, $30000.0 in Q4 2025, and -$94000.0 in Q3 2025.